US011759502B2

(12) **United States Patent**
Vilhelmsen et al.

(10) **Patent No.: US 11,759,502 B2**
(45) **Date of Patent: *Sep. 19, 2023**

(54) **COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOF**

(71) Applicant: **Novo Nordisk A/S**, Bagsvaerd (DK)

(72) Inventors: **Thomas Vilhelmsen**, Strand (DK); **Helle Eliasen**, Koege (DK); **Tue Hansen**, Copenhagen (DK)

(73) Assignee: **Novo Nordisk A/S**, Bagsvaerd (DK)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **17/719,610**

(22) Filed: **Apr. 13, 2022**

(65) **Prior Publication Data**

US 2022/0331404 A1 Oct. 20, 2022

Related U.S. Application Data

(63) Continuation of application No. 17/157,363, filed on Jan. 25, 2021, which is a continuation of application No. 14/386,589, filed as application No. PCT/EP2013/055362 on Mar. 15, 2013, now Pat. No. 10,933,120.

(60) Provisional application No. 61/748,840, filed on Jan. 4, 2013.

(30) **Foreign Application Priority Data**

Mar. 22, 2012 (EP) 12160743
Jan. 31, 2013 (EP) 13153459

(51) **Int. Cl.**
A61K 38/26 (2006.01)
A61K 9/20 (2006.01)
A61K 31/20 (2006.01)

(52) **U.S. Cl.**
CPC ***A61K 38/26*** (2013.01); ***A61K 9/2013*** (2013.01); ***A61K 9/2077*** (2013.01); ***A61K 31/20*** (2013.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,545,618 A 8/1996 Buckley et al.
5,574,010 A 11/1996 McFadden
5,604,203 A 2/1997 Balasubramaniam
5,650,386 A 7/1997 Leone-Bay et al.
5,773,647 A 6/1998 Leone-Bay et al.
5,866,536 A 2/1999 Leone-Bay et al.
5,968,899 A 10/1999 Sekine et al.
6,046,167 A 4/2000 Balasubramaniam
6,071,510 A 6/2000 Leone-Bay et al.
6,268,343 B1 7/2001 Knudsen et al.
6,458,924 B2 10/2002 Knudsen et al.
7,049,283 B2 5/2006 Ault et al.
7,235,627 B2 6/2007 Knudson et al.
7,271,149 B2 9/2007 Glaesner et al.
7,417,028 B2 8/2008 Ewing et al.
8,022,035 B2 9/2011 Schwartz et al.
8,039,018 B2 10/2011 Majuru et al.
8,053,429 B2 11/2011 Cumming et al.
8,097,698 B2 1/2012 Knudsen et al.
8,536,122 B2 9/2013 Lau et al.
8,648,041 B2 2/2014 Garibay et al.
8,895,694 B2 11/2014 Spetzler et al.
8,901,073 B2 12/2014 Bloom
9,067,977 B2 6/2015 Spetzler et al.
9,085,637 B2 7/2015 Oestergaard et al.
9,186,392 B2 11/2015 Klein et al.
9,266,940 B2 2/2016 Wieczorek et al.
9,278,123 B2 3/2016 Sauerberg et al.
9,527,900 B2 12/2016 Linderoth et al.
9,993,430 B2 6/2018 Jensen et al.
10,005,827 B2 6/2018 Spetzler et al.
10,086,047 B2 10/2018 Sauerberg et al.
10,246,497 B2 4/2019 Oestergaard et al.
10,278,923 B2 5/2019 Nielsen et al.
10,335,369 B2 7/2019 Vilhelmsen
10,933,120 B2 3/2021 Vilhelmsen et al.
10,960,052 B2 3/2021 Sauerberg et al.
11,033,499 B2 6/2021 Jensen et al.
11,034,746 B2 6/2021 Wieczorek et al.
11,117,947 B2 9/2021 Wieczorek et al.
(Continued)

FOREIGN PATENT DOCUMENTS

CN 1190893 A 8/1998
CN 1867360 A 11/2006
(Continued)

OTHER PUBLICATIONS

King, Simon, "Viewpoints: Novo Nordisk R&D chief predicts an oral revolution for biologies" Nov. 14, 2018, Available from: [http://www.firstwordpharma.com/print/1604592?tsid=17].
Lee, Hye J., "Protein Drug Oral Delivery: The Recent Progress" Archives of Pharmacal Research, 2002, vol. 25, No. 5, pp. 572-584.
Madsen, Kjeld et al., "Structure—Activity and Protraction Relationship of Long-Acting Glucagon-like Peptide-1 Derivatives: Importance of Fatty Acid Lenght, Polarity, and Bulkiness" J. Med. Chem., 2007, vol. 50, pp. 6126-6132.
Morishita, Mariko et al., "Is the oral route possible for peptide and protein drug delivery?" Drug Discovery Today, Oct. 2006, vol. 11, No. 19/20, pp. 905-910.
(Continued)

Primary Examiner — Thomas S Heard
(74) *Attorney, Agent, or Firm* — Leon Y. Lum

(57) **ABSTRACT**

The invention relates to pharmaceutical compositions comprising a first type of granules and a second type of granules, wherein said first type of granules comprises a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and no GLP-1 peptide, and wherein said second type of granules comprises a GLP-1 peptide and no salt of N-(8-(2-hydroxybenzoyl) amino)caprylic acid, as well as the intermediate granules, processes for the preparation of the granules and compositions, and use thereof in medicine.

28 Claims, No Drawings

Specification includes a Sequence Listing.